Ensuring exchangeability in data-based priors for a Bayesian analysis of clinical trials

PHARMACEUTICAL STATISTICS(2022)

引用 14|浏览1
暂无评分
摘要
In many orphan diseases and pediatric indications, the randomized controlled trials may be infeasible because of their size, duration, and cost. Leveraging information on the control through a prior can potentially reduce sample size. However, unless an objective prior is used to impose complete ignorance for the parameter being estimated, it results in biased estimates and inflated type-I error. Hence, it is essential to assess both the confirmatory and supplementary knowledge available during the construction of the prior to avoid "cherry-picking" advantageous information. For this purpose, propensity score methods are employed to minimize selection bias by weighting supplemental control subjects according to their similarity in terms of pretreatment characteristics to the subjects in the current trial. The latter can be operationalized through a proposed measure of overlap in propensity-score distributions. In this paper, we consider single experimental arm in the current trial and the control arm is completely borrowed from the supplemental data. The simulation experiments show that the proposed method reduces prior and data conflict and improves the precision of the of the average treatment effect.
更多
查看译文
关键词
Bayesian augmented control, exchangeability, Hellinger distance, historical control, propensity score, real-world data
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要